[1]郭浩山 岳海振 郑大伟 刘桂杰 孙建陈文祥 董吉哲 周占国△ 刘刚 关涛.地杞壮骨胶囊治疗早中期股骨头坏死的临床研究[J].中国中医骨伤科杂志,2020,28(10):30-34.
　GUO Haoshan YUE Haizhen ZHENG Dawei LIU Guijie SUN Jian CHEN Wenxiang DONG Jizhe ZHOU Zhanguo LIU Gang GUAN Tao.Clinical Study on the Therapy of Diqi Zhuanggu Capsules for Osteonecrosis of the Femoral Head at Early and Middle Stages[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2020,28(10):30-34.
点击复制

地杞壮骨胶囊治疗早中期股骨头坏死的临床研究()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第28卷
期数:
2020年10期
页码:
30-34
栏目:
临床研究
出版日期:
2020-10-10

文章信息/Info

Title:
Clinical Study on the Therapy of Diqi Zhuanggu Capsules for Osteonecrosis of the Femoral Head at Early and Middle Stages
文章编号:
1005-0205(2020)10-0030-05
作者:
郭浩山1 岳海振1 郑大伟1 刘桂杰1 孙建1陈文祥1 董吉哲1 周占国1△ 刘刚1 关涛1
Author(s):
GUO Haoshan1 YUE Haizhen1 ZHENG Dawei1 LIU Guijie1 SUN Jian1 CHEN Wenxiang1 DONG Jizhe1 ZHOU Zhanguo1△ LIU Gang1 GUAN Tao1
1Department of Orthopedics,Liaocheng Hospital of Traditional Chinese Medicine,Liaocheng 252000,Shandong China.
关键词:
股骨头坏死;  补气;  益肾;  活血
Keywords:
osteonecrosis of the femoral head;  invigorating qi;  reinforcing kidney;  activating blood
分类号:
R681.8
文献标志码:
A
摘要:
目的:观察地杞壮骨胶囊治疗早中期股骨头坏死的疗效。方法:自2017年4月至2018年3月,将100例(156髋)ARCOⅠ,Ⅱ期股骨头坏死患者随机分为试验组与对照组。试验组共50例(76髋),其中男43例,女7例; 年龄21～60岁,平均(46.22±8.68)岁; 口服本院自制中成药制剂地杞壮骨胶囊治疗。对照组共50例(80髋),其中男37例,女13例; 年龄22～60岁,平均(46.76±9.92)岁; 口服通络生骨胶囊治疗。分别记录治疗前及治疗后访视时影像学转归、WOMAC及Harris评分,观察优良率,进行疗效比较。结果:共有86例患者按照计划获得完整随访。两组在开始治疗后第3,6,9个月时影像学转归差异无统计学意义(P>0.05)。末次随访时,两组均有约70%的患者影像学表现稳定,约20%的患者加重,约10%的患者好转。两组治疗后的WOMAC及Harris评分与治疗前相比,差异均有统计学意义(P<0.05),治疗后得分均优于治疗前。两组间不同访视期WOMAC与Harris评分差异无统计学意义(P>0.05)。参照Harris髋关节评分系统评分,末次随访时试验组优37髋,良16髋,可6髋,差10髋,优良率76.81%; 对照组优28髋,良14髋,可12髋,差12髋,优良率63.64%。经Ridit分析,两组疗效比较差异无统计学意义(P>0.05)。结论:两种药物对早中期股骨头坏死的治疗均有效,且疗效相当。采用补气益肾活血法治疗早中期股骨头坏死能够取得令人满意的疗效。
Abstract:
To observe the efficacy of the therapy of Diqi Zhuanggu capsules for osteonecrosis of the femoral head at early and middle stages.Methods:100 patients(156 hips)diagnosed as osteonecrosis of the femoral head at ARCO Ⅰ,Ⅱ stages were randomly divided into test group and control group from April 2017 to March 2018.In the test group,there were 43 male and 7 female aged from 21～60 years old with an average of(46.22±8.68)years treated with Diqi Zhuanggu capsules.In the control group,there were 37 male and 13 female aged from 22～60 years old with an average of(46.76±9.92)years treated with Tongluo Shenggu capsules.The imaging,WOMAC and Harris scores were recorded before and after the treatment,and the excellent and good rates were observed to be compared.Results:A total of 86 patients were followed up in all.There were no significant differences in imaging outcome between the two groups at 3rd,6th,and 9th month after starting treatment(P>0.05).At the last follow-up,about 70% of the patients in both groups had stable imaging performance,about 20% of patients aggravated and about 10% of patients improved.After treatment,the WOMAC and Harris scores of the two groups were significantly different before treatment(P<0.05).The scores after treatment were better than those before treatment.There were no significant differences in WOMAC and Harris scores between the two groups at different visit periods(P>0.05).With reference to the Harris hip scoring system,at the last follow-up,the test group revealed excellent at 37 hips,good at 16 hips,fair at 6 hips,and poor at 10 hips,which showed the excellent and good rate with 76.81%; the control group showed excellent at 28 hips,good at 14 hips,fair at 12 hips and poor at 12 hips,with excellent and good rate of 63.64%.According to Ridit analysis,there was no significant difference in efficacy between the two groups(P>0.05).Conclusion:Both drugs are effective in the treatment of osteonecrosis of the femoral head in the early and middle stages,and have similar effects.Diqi Zhuanggu capsules can treat osteonecrosis of the femoral head in the early and middle stages to obtain satisfactory results.

参考文献/References:

[1] 中华医学会骨科学分会关节外科学组.股骨头坏死临床诊疗规范[J].中国矫形外科杂志,2016,24(1):49-54.
[2] LARSON E,JONES L C,GOODMAN S B,et al.Early-stage osteonecrosis of the femoral head:where are we and where are we going in year 2018?[J].Int Orthop,2018,42(7):1723-1728.
[3] 何伟.如何把握股骨头坏死患者的保髋治疗时机[J].中国骨与关节杂志,2016,5(2):82-86.
[4] 中华老年骨科与康复电子杂志编辑委员会.股骨头坏死保髋治疗指南(2016版)[J].中华老年骨科与康复电子杂志,2016,2(2):65-70.
[5] 中华中医药学会.股骨头坏死中医辨证标准(2019年版)[J].中医正骨,2019,31(6):1-2.
[6] 尹晨东,薛凡,邓豪,等.仇湘中教授治疗非创伤性股骨头坏死经验浅析[J].中国中医骨伤科杂志,2019,27(8):79-80.
[7] 王晨,施杞.施杞辨治股骨头坏死经验撷菁[J].上海中医药杂志,2015,49(11):1-3.
[8] 陈良飞,胡盼盼,郭会卿.郭会卿教授治疗非创伤性股骨头坏死经验总结[J].风湿病与关节炎,2019,8(8):44-46.
[9] 陈卫衡,周宇,何海军,等.健脾活骨方治疗早中期非创伤性股骨头坏死临床回顾性研究[J].中国中西医结合杂志,2013,33(8):1054-1058.
[10] 何伟,李博宁.李同生名老中医治疗股骨头坏死经验浅析[J].时珍国医国药,2015,27(1):207-209.
[11] MONT M A,HUNGERFORD D S.Non-tranmatie avascular necrosis of the femoral head[J].J Bone Joint Surg(Am),1995,77:459.
[12] 陈卫衡,谢斌,刘道兵,等.髓芯减压植骨术治疗股骨头坏死临床疗效的动态研究[J].中华关节外科杂志:电子版,2014,8(5):578-584.
[13] 樊粤光.股骨头缺血性坏死与袁浩教授的学术思想[J].新中医,1996(10):13-14.
[14] 樊粤光,袁浩.股骨头缺血性坏死病因病机及治疗方法的分析评述[J].广州中医学院学报,1991,8(l):57.
[15] 陈卫衡,刘道兵,张洪美,等.股骨头坏死的三期四型辨证思路[J].中国中医基础医学杂志,2003,9(l2):51-52.
[16] 元唯安,杜炯,闻辉,等.通络生骨胶囊治疗股骨头坏死(筋脉瘀滞证)的多中心随机、双盲、双模拟、阳性药对照临床研究[J].上海中医药杂志,2019,53(8):53-59.
[17] 陈达,陈晓波,白昱旸,等.通络生骨胶囊促进兔激素性股骨头坏死修复的机制研究[J].中药新药与临床药理,2016,27(3):351-356.

备注/Memo

备注/Memo:
(收稿日期:2020-02-08)基金项目:国家中医临床研究基地业务建设第二批科研专项 课题(JDZX2015282) 中国中医科学院科技创新团队建设项目(YS1304) 1山东省聊城市中医医院(山东 聊城,252000) △通信作者 E-mail:13869568383@126.com
更新日期/Last Update: 2020-10-10